Financial Contrast: OncoGenex Pharmaceuticals (ACHV) and The Competition
OncoGenex Pharmaceuticals (NASDAQ: ACHV) is one of 199 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare OncoGenex Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, earnings, analyst recommendations, profitability, risk and valuation.
Volatility and Risk
OncoGenex Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, OncoGenex Pharmaceuticals’ rivals have a beta of 1.62, suggesting that their average share price is 62% more volatile than the S&P 500.
This table compares OncoGenex Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|OncoGenex Pharmaceuticals Competitors||-4,032.19%||-118.84%||-43.83%|
Insider and Institutional Ownership
46.9% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 35.8% of OncoGenex Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares OncoGenex Pharmaceuticals and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|OncoGenex Pharmaceuticals||$5.06 million||-$20.12 million||-0.31|
|OncoGenex Pharmaceuticals Competitors||$193.08 million||-$40.19 million||3.67|
OncoGenex Pharmaceuticals’ rivals have higher revenue, but lower earnings than OncoGenex Pharmaceuticals. OncoGenex Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and recommmendations for OncoGenex Pharmaceuticals and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|OncoGenex Pharmaceuticals Competitors||484||2290||6255||120||2.66|
As a group, “Biotechnology & Medical Research” companies have a potential downside of 0.27%. Given OncoGenex Pharmaceuticals’ rivals higher possible upside, analysts plainly believe OncoGenex Pharmaceuticals has less favorable growth aspects than its rivals.
OncoGenex Pharmaceuticals beats its rivals on 5 of the 9 factors compared.
About OncoGenex Pharmaceuticals
Achieve Life Sciences, Inc., formerly OncoGenex Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27).
Receive News & Ratings for OncoGenex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.